TPST
NASDAQTempest Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.02+0.14 (+7.45%)
02:30 PM07:45 PM
News · 26 weeks52-50%
2025-11-022026-04-26
Mix2990d
- SEC Filings15(52%)
- Other6(21%)
- Insider5(17%)
- Offering2(7%)
- Leadership1(3%)
Latest news
25 items- PRTempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual MeetingPresentation will showcase recent data from multiple clinical studies evaluating dual-targeting CD19/BCMA CAR-T therapy candidate TPST-2003Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with relapsed/refractory multiple myelomaData further support potential of TPST-2003 to improve outcomes for patients with extramedullary disease BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest") will present its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell ("CAR-T") therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (
- PRTempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-TDelivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal developmentTech transfer on track to support initiation of potentially registrational study in Q4 2026Key manufacturing milestone follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% complete response in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced C
- PRTempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing EffortsAdds dedicated business development leadership to support Tempest's strategic prioritiesWill lead China outreach and cross-border partnership effortsTo support ongoing partnering discussions for Phase 3-ready amezalpat program, including potential China development opportunities BRISBANE, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced the appointment of Andrew Fang, Ph.D., as Head of Business Development. Dr. Fang will lead Tempest's global business development efforts, including strategic partners
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form 424B3 filed by Tempest Therapeutics Inc.424B3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form EFFECT filed by Tempest Therapeutics Inc.EFFECT - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form D filed by Tempest Therapeutics Inc.D - Tempest Therapeutics, Inc. (0001544227) (Filer)
- INSIDERSEC Form 4 filed by Trojanowski Justin4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- INSIDERSEC Form 4 filed by Maestas Nicholas4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- SECSEC Form S-3 filed by Tempest Therapeutics Inc.S-3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-8 POS filed by Tempest Therapeutics Inc.S-8 POS - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-3 filed by Tempest Therapeutics Inc.S-3 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECSEC Form S-8 filed by Tempest Therapeutics Inc.S-8 - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Reports Year End 2025 Financial Results and Provides Business UpdateCompleted strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003 in patients with relapsed/refractory multiple myeloma (rrMM) BRISBANE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today reported financial results for the year ended December 31, 2025, and provided a corporate update. "2025 was a transformative year for Tempest as we stre
- SECSEC Form 10-K filed by Tempest Therapeutics Inc.10-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- INSIDERSEC Form 4 filed by Angel Matthew4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Therapeutics Announces Up To $6 Million Private PlacementBRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) (the "Company"), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 925,927 shares of common stock (or pre-funded warrant in lieu thereof), series A warrants to purchase up to 925,927 shares of common stock and short-term series B warrants to purchase up to 925,927 shares of common stock, at a combined purchase price of $2.16 per share of common stock (or $2.159 per pre-funded warrant in lieu thereof) and accompanyi
- PRTempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturingAll activities other than long-term stability testing planned to be complete in Q3 2026 to support potential IND filing in Q4 2026Selection of tech transfer partner follows Tempest's recent announcement of positive interim data from the ongoing REDEEM-1 Phase 1/2a trial of TPST-2003, including 100% CR in all six efficacy evaluable patients, and accelerated development timeline BRISBANE, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced C
- SECSEC Form 8-K filed by Tempest Therapeutics Inc.8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade >3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression free survival (PFS) of 23.1 months, including in patients with extramedullary disease36 patients with relapsed/refractory multiple myeloma treated to date across two studiesTempest plans to submit a U.S. IND and, subject to clearance, initiate a U.S. registrational study in 2026 BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and small molecule product ca
- SECTempest Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)
- PRTempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T AssetsTempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assetsDevelopment approach prioritizes partner-funded and externally supported programs to generate clinical data before deploying significant internal capitalPipeline expansion includes TPST-4003, an in vivo dual-targeting CD19/BCMA CAR-T, with potential near-term milestones BRISBANE, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST) ("Tempest"), a clinical-stage biotechnology company with a diversified portfolio of cell therapy and small molecule product candidates, today outlined its post-transaction strategy to advan
TPST FAQ
6 questionsWhat does Tempest Therapeutics Inc. do?
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha, and is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company is headquartered in South San Francisco, California.Where does TPST stock trade?
Tempest Therapeutics Inc. (TPST) is listed on NASDAQ.What sector and industry is TPST in?
Tempest Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TPST?
Tempest Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1100.00 price target on 2026-01-22. Recent price targets range from $1100.00 to $1500.00.What companies are similar to TPST?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare TPST side-by-side with any of them on Quantisnow.How can I track TPST on Quantisnow?
Quantisnow aggregates Tempest Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TPST to receive live email and push alerts on every new disclosure.